Latest news with #ARX
Yahoo
26-05-2025
- Business
- Yahoo
Aroa Biosurgery Limited's (ASX:ARX) largest shareholders are retail investors with 46% ownership, institutions own 29%
The considerable ownership by retail investors in Aroa Biosurgery indicates that they collectively have a greater say in management and business strategy 50% of the business is held by the top 13 shareholders Insiders own 25% of Aroa Biosurgery We check all companies for important risks. See what we found for Aroa Biosurgery in our free report. If you want to know who really controls Aroa Biosurgery Limited (ASX:ARX), then you'll have to look at the makeup of its share registry. With 46% stake, retail investors possess the maximum shares in the company. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). Meanwhile, institutions make up 29% of the company's shareholders. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. Let's take a closer look to see what the different types of shareholders can tell us about Aroa Biosurgery. View our latest analysis for Aroa Biosurgery Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices. Aroa Biosurgery already has institutions on the share registry. Indeed, they own a respectable stake in the company. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Aroa Biosurgery, (below). Of course, keep in mind that there are other factors to consider, too. Aroa Biosurgery is not owned by hedge funds. The company's CEO Brian Ward is the largest shareholder with 9.6% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 8.8% and 6.5%, of the shares outstanding, respectively. Looking at the shareholder registry, we can see that 50% of the ownership is controlled by the top 13 shareholders, meaning that no single shareholder has a majority interest in the ownership. While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future. The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves. I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions. Our information suggests that insiders maintain a significant holding in Aroa Biosurgery Limited. Insiders own AU$39m worth of shares in the AU$157m company. This may suggest that the founders still own a lot of shares. You can click here to see if they have been buying or selling. The general public-- including retail investors -- own 46% stake in the company, and hence can't easily be ignored. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders. I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Many find it useful to take an in depth look at how a company has performed in the past. You can access this detailed graph of past earnings, revenue and cash flow. Ultimately the future is most important. You can access this free report on analyst forecasts for the company. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
26-05-2025
- Business
- Yahoo
Aroa Biosurgery Limited's (ASX:ARX) largest shareholders are retail investors with 46% ownership, institutions own 29%
The considerable ownership by retail investors in Aroa Biosurgery indicates that they collectively have a greater say in management and business strategy 50% of the business is held by the top 13 shareholders Insiders own 25% of Aroa Biosurgery We check all companies for important risks. See what we found for Aroa Biosurgery in our free report. If you want to know who really controls Aroa Biosurgery Limited (ASX:ARX), then you'll have to look at the makeup of its share registry. With 46% stake, retail investors possess the maximum shares in the company. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). Meanwhile, institutions make up 29% of the company's shareholders. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. Let's take a closer look to see what the different types of shareholders can tell us about Aroa Biosurgery. View our latest analysis for Aroa Biosurgery Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices. Aroa Biosurgery already has institutions on the share registry. Indeed, they own a respectable stake in the company. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Aroa Biosurgery, (below). Of course, keep in mind that there are other factors to consider, too. Aroa Biosurgery is not owned by hedge funds. The company's CEO Brian Ward is the largest shareholder with 9.6% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 8.8% and 6.5%, of the shares outstanding, respectively. Looking at the shareholder registry, we can see that 50% of the ownership is controlled by the top 13 shareholders, meaning that no single shareholder has a majority interest in the ownership. While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future. The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves. I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions. Our information suggests that insiders maintain a significant holding in Aroa Biosurgery Limited. Insiders own AU$39m worth of shares in the AU$157m company. This may suggest that the founders still own a lot of shares. You can click here to see if they have been buying or selling. The general public-- including retail investors -- own 46% stake in the company, and hence can't easily be ignored. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders. I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Many find it useful to take an in depth look at how a company has performed in the past. You can access this detailed graph of past earnings, revenue and cash flow. Ultimately the future is most important. You can access this free report on analyst forecasts for the company. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Time of India
21-05-2025
- Automotive
- Time of India
Oben to foray into 100-cc motorcycle segment
Oben Electric is set to enter the 100-cc motorcycle segment with its new O100 platform, targeting the mass commuter base with sub-Rs 1 lakh electric motorcycles expected in the second half of the year. This move aims to capture a significant 30% share of the two-wheeler market. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Electric motorcycle maker Oben on Wednesday announced plans to foray into the 100-cc motorcycle segment under a new platform. The new platform named as O100 will produce the 100 cc and equivalent sub-Rs 1 lakh motorcycles, which are expected to be rolled out by the second half this calendar year, to cater to the mass commuter base, Oben Electric segment accounts for nearly 30 per cent of the total two-wheeler market, it first motorcycle platform, ARX, churns out the performance-centric Rorr and Rorr EZ models of e-motorcycles that cater to the premium commuter scalability at its core, enabling faster product iterations and manufacturing ramp-up, the platform allows Oben Electric to deliver high-quality electric motorcycles that cater to a wide range of commuter a modular and versatile architecture, O100 supports multiple variants, different battery options, and functionalities tailored to different customer segments, it said, adding that with future-ready by design, the platform also allows seamless integration of emerging technologies and infrastructure upgrades, making it a robust foundation for long-term EV adoption in India's most cost-sensitive segments."Our new platform, O100 is engineered for India's mass daily commuters and aims to make electric motorcycles a practical reality for every Indian," Oben Electric Founder and CEO Madhumita Agrawal Electric also said it is rapidly expanding its presence across Tier I/II/III cities and looking to cross 100+ showrooms by the end of the year.
Yahoo
12-02-2025
- Automotive
- Yahoo
With war on their doorstep, European defense tech startups are gunning for a slice of growing military budgets
With defense budgets rising in Western countries, major contractors like Germany's Rheinmetall are in for growing sales. But smaller companies, too, could get a piece of the war pie. Munich-based dual-use startup ARX Robotics is one of these. Its technology helps convert traditional military equipment like trucks and tanks into unmanned, autonomous vehicles. This allows for safer reconnaissance, logistics, and combat in high-risk areas like Ukraine's front line. 'We cannot wait for the replacement because, for example, the runtime for a tank is 30 to 50 years. And this means you cannot afford to replace them with new modern digitized or AI-capable systems unless you wait for decades,' said its co-founder and CEO, Marc Wietfeld. This is where ARX comes in with Mithra OS, an AI-based operating system it claims can transform legacy military vehicles into autonomous units. 'It saves costs — more than 95 percent — and also time,' Wietfeld claimed. 'It takes us only a few weeks […] to digitize the system.' Wietfeld was inspired by his experience in the German army, where he served for 14 years, but saw 'outdated' equipment. As a self-described 'European resilience builder,' this left him concerned, as did recent developments. "I think that the biggest problem is that we are outnumbered and outpaced by our adversaries.' Finance lead, Maximilian Wied (L), CEO and Co-Founder, Marc Wietfeld and COO and Co-Founder, Stefan Roebel: ARX wants to produce unmanned ground systems at scale, and recently opened a new production facility in Munich to do so, but it won't do it on its own. Instead, it partnered with fellow German startup Quantum Systems and with several major defense contractors, known as 'primes'. For instance, it teamed up with Thales to integrate and enhance its ground radar in what Wietfeld describes as 'a win-win-win' for ARX and the armed forces, which saved money, but also had a good outcome for ARX and Thales. Compared to primes, ARX can iterate much more quickly. It doesn't have all the answers, but it can correct the course fast. When it launched in Ukraine last year, ARX's system failed dramatically on the battlefield. Four months of work followed 'to adapt the system to the requirements of reality instead of the requirements of the procurement office of a NATO force.' 'It saves costs—more than 95 percent—and also time." Co-founder and CEO, Marc Wietfeld This worked, and ARX was awarded a major contract. It also secured €9 million in seed funding from investors, including the NATO Innovation Fund, and is now in talks to raise a Series A round of investment. But it also keeps on iterating. 'We change our software stack every two to three weeks because this is the speed of adapting needed to be successful on the battlefield.' This is also a differential compared to the larger primes, Wietfeld said. 'Investors ask me one thing: Why are you successful and why is Rheinmetall not doing the same and killing your business? And my answer is, it's a structural advantage a lean and fast startup has. We are building software-defined systems so it's easy for us to do that because the core of the system is software, not hardware.' 'We change our software stack every two to three weeks because this is the speed of adapting needed to be successful on the battlefield.' Marc Wietfeld Another advantage is iteration speed, which Wietfeld sees as directly tied to ARX's business model. 'We are not waiting for the processes of the procurement office telling us what to do,' he said. Like all European defense companies, it still has to deal with a much more fragmented market than the U.S. But rather than fighting it, ARX is embracing it in its expansion strategy. 'We are building small entities all over Europe because [each of them needs] to be adapted to its customer and to its supply chain,' Wietfeld stated, 'but also [because] by being small and adaptive they are much faster than having one big HQ managing the whole world from Munich.' Staying lean and fast is a strong advantage; but according to former CIA senior operations officer James Acuna, this might come at the expense of proper support for end users. 'Miltech startups, especially those that have explosive growth, fail to adequately prepare or address customer service concerns or follow up,' Acuna cautioned. 'Too often it's up to you to fix your own unmanned systems or get your drone out of customs if there's an issue. Conversely, Lockheed Martin with a market capitalization of $117 billion has probably 10 percent of the company allocated to [customer service], including a 24/7 hot desk,' said Acuna, now a security consultant. Not excelling at unscalable customer support isn't unique to defense startups; good luck getting Meta on the phone if your Instagram account gets hacked. But when lives are on the line, this gives primes an advantage. 'If the little startups are ever going to compete with the big guys, they need to offer the same services including long-term financing etc,' Acuna observed. Instead of doing that, some might be tempted to become an additional offering on top of what primes already do. With tech IPOs far and few between as is, this makes M&As a plausible option if incumbents want to move faster while providing newcomers with the customer service layer they lack. However, Wietfeld hopes some defense tech startups will go public instead. 'As a founder, of course, I would like to see a defense IPO in Europe.' It is too early to say which path ARX will pursue, but its ambition is clear: 'We are on the way to becoming a new defense prime for the land domain,' Wietfeld said. This story was originally featured on
